DOP2013000246A - Modulación de la expresión del virus de la hepatitis b (vhb) - Google Patents
Modulación de la expresión del virus de la hepatitis b (vhb)Info
- Publication number
- DOP2013000246A DOP2013000246A DO2013000246A DO2013000246A DOP2013000246A DO P2013000246 A DOP2013000246 A DO P2013000246A DO 2013000246 A DO2013000246 A DO 2013000246A DO 2013000246 A DO2013000246 A DO 2013000246A DO P2013000246 A DOP2013000246 A DO P2013000246A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- hbv
- hepatitis
- modulation
- virus expression
- methods
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478038P | 2011-04-21 | 2011-04-21 | |
| US201161478040P | 2011-04-21 | 2011-04-21 | |
| US201261596690P | 2012-02-08 | 2012-02-08 | |
| US201261596692P | 2012-02-08 | 2012-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2013000246A true DOP2013000246A (es) | 2014-04-30 |
Family
ID=47041953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2013000246A DOP2013000246A (es) | 2011-04-21 | 2013-10-21 | Modulación de la expresión del virus de la hepatitis b (vhb) |
Country Status (35)
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| MX341084B (es) | 2009-11-02 | 2016-08-05 | Univ Washington | Composiciones de nucleasas terapéuticas y métodos. |
| US9029341B2 (en) * | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| ES2666303T3 (es) | 2011-04-29 | 2018-05-03 | University Of Washington | Composiciones terapéuticas de nucleasa y métodos |
| EA024762B9 (ru) | 2011-06-30 | 2017-04-28 | Эрроухэд Рисерч Корпорейшн | Композиции и способы ингибирования экспрессии генов вируса гепатита в |
| US10202599B2 (en) | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| WO2013159108A2 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| SG11201501255PA (en) | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| US9695418B2 (en) | 2012-10-11 | 2017-07-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
| CN104968783B (zh) | 2012-10-15 | 2019-12-10 | Ionis制药公司 | 用于调节c9orf72表达的组合物 |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| AU2014211406B2 (en) | 2013-01-30 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | LNA oligonucleotide carbohydrate conjugates |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| WO2015042447A1 (en) | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| US10221414B2 (en) | 2013-10-11 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| HUE050704T2 (hu) * | 2014-04-01 | 2020-12-28 | Biogen Ma Inc | Összetételek a SOD-1 expressziójának modulálására |
| EA036496B1 (ru) | 2014-05-01 | 2020-11-17 | Ионис Фармасьютикалз, Инк. | Конъюгированные олигонуклеотиды для модулирования экспрессии фактора комплемента b |
| US9382540B2 (en) | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
| KR102545316B1 (ko) * | 2014-11-10 | 2023-06-22 | 알닐람 파마슈티칼스 인코포레이티드 | Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법 |
| EA039127B1 (ru) * | 2015-03-24 | 2021-12-08 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RS60230B1 (sr) * | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| KR20250078597A (ko) | 2015-11-06 | 2025-06-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포리포프로테인 (a) 발현 조정 |
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| RU2747822C2 (ru) | 2016-03-14 | 2021-05-14 | Ф. Хоффманн-Ля Рош Аг | Олигонуклеотиды для понижения экспрессии pd-l1 |
| EP4219767A1 (en) | 2016-06-17 | 2023-08-02 | F. Hoffmann-La Roche AG | Papd5 and papd7 inhibitors for treating a hepatitis b infection |
| CA3029627A1 (en) | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| KR102533038B1 (ko) * | 2016-09-14 | 2023-05-17 | 얀센 바이오파마, 인크. | 변형된 올리고뉴클레오티드 및 사용 방법 |
| US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| CN110234763A (zh) * | 2016-11-11 | 2019-09-13 | 詹森生物制药有限公司 | 针对hbv cccdna的寡核苷酸靶向策略 |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| MX2019006803A (es) * | 2016-12-13 | 2019-11-18 | Am Sciences Inc | Composicion farmaceutica para prevenir o tratar la hepatitis b. |
| BR112019012057A2 (pt) | 2016-12-15 | 2019-11-12 | Meharry Medical College | agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv) |
| CN106729753A (zh) * | 2016-12-16 | 2017-05-31 | 谭旭 | 抗乙型肝炎病毒的递送系统和生物制剂 |
| CN106701763B (zh) * | 2016-12-30 | 2019-07-19 | 重庆高圣生物医药有限责任公司 | CRISPR/Cas9靶向敲除人乙肝病毒P基因及其特异性gRNA |
| CN106916905B (zh) * | 2017-01-17 | 2018-06-08 | 重庆医科大学附属儿童医院 | 隐匿性乙肝病毒检测试剂盒及其检测方法 |
| CA3059446A1 (en) | 2017-04-18 | 2018-10-25 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| CA3073537A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
| JP7332585B2 (ja) * | 2017-09-01 | 2023-08-23 | アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） | Ｂ型肝炎ウイルス感染症を予防し且つ／又は処置するのに使用するための阻害剤 |
| CN111511914B (zh) | 2017-10-16 | 2023-11-17 | 豪夫迈·罗氏有限公司 | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 |
| UA128786C2 (uk) | 2017-10-20 | 2024-10-23 | Дайсерна Фармасьютикалз, Інк | Олігонуклеотид для лікування інфекції гепатиту в |
| WO2019157531A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| SG11202009680XA (en) | 2018-04-05 | 2020-10-29 | Hoffmann La Roche | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| US20210047646A1 (en) * | 2018-04-09 | 2021-02-18 | The Trustees Of Princeton University | Compositions Comprising Immune System Activators and Method of Using Same |
| PE20210346A1 (es) | 2018-07-03 | 2021-02-25 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau |
| CN112534055A (zh) | 2018-07-13 | 2021-03-19 | 豪夫迈·罗氏有限公司 | 用于调节rtel1表达的寡核苷酸 |
| JP7625512B2 (ja) | 2018-08-13 | 2025-02-03 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法 |
| CN109234275A (zh) * | 2018-08-30 | 2019-01-18 | 山东省立医院 | 一种可以同时抑制乙肝病毒dna和乙肝表面抗原的反义核苷酸 |
| CA3132601A1 (en) * | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
| EP3947680A2 (en) * | 2019-04-03 | 2022-02-09 | Bristol-Myers Squibb Company | Angptl2 antisense oligonucleotides and uses thereof |
| SG11202112741XA (en) | 2019-05-31 | 2021-12-30 | Aligos Therapeutics Inc | Modified gapmer oligonucleotides and methods of use |
| WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Ｂ型肝炎治療用核酸分子 |
| WO2021122735A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sept9 inhibitors for treating hepatitis b virus infection |
| EP4077669A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of sbds inhibitors for treating hepatitis b virus infection |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| JP2023506954A (ja) | 2019-12-19 | 2023-02-20 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用 |
| WO2021122869A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of scamp3 inhibitors for treating hepatitis b virus infection |
| WO2021226019A2 (en) * | 2020-05-04 | 2021-11-11 | The Regents Of The University Of California | Compositions and methods for treating viral infections |
| AU2021318943A1 (en) * | 2020-07-27 | 2023-03-02 | Aligos Therapeutics, Inc. | HBV binding oligonucleotides and methods of use |
| CN116157522A (zh) | 2020-08-21 | 2023-05-23 | 豪夫迈·罗氏有限公司 | A1cf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| JP2024518788A (ja) * | 2021-05-10 | 2024-05-02 | キュー－ステート バイオサイエンシーズ， インコーポレイテッド | ナトリウムチャネル１．６を標的とする組成物 |
| CA3235672A1 (en) * | 2021-11-29 | 2023-06-01 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| TW202340468A (zh) * | 2022-01-10 | 2023-10-16 | 中國大陸商杭州浩博醫藥有限公司 | B型肝炎病毒(hbv)表現之調節 |
| US20250092401A1 (en) | 2022-01-28 | 2025-03-20 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy for treating hepatitis b virus infections |
| KR20240168390A (ko) | 2022-03-29 | 2024-11-29 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 만성 b형 간염을 치료하는 방법 |
| AU2024255686A1 (en) | 2023-04-12 | 2025-10-23 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating chronic hepatitis b |
| CN119816597A (zh) * | 2023-08-10 | 2025-04-11 | 石药集团中奇制药技术（石家庄）有限公司 | 一种抑制HBV基因表达的dsRNA分子及其应用 |
| CN118667808B (zh) * | 2023-08-22 | 2025-04-18 | 浙江柏拉阿图医药科技有限公司 | 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| WO2025061204A1 (zh) * | 2023-09-21 | 2025-03-27 | 华辉安健（北京）生物科技有限公司 | 用于hbv相关疾病的化合物及其应用 |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
| WO2025262623A1 (en) | 2024-06-21 | 2025-12-26 | Glaxosmithkline Intellectual Property Development Limited | Method of treating hbv/hiv coinfection |
| CN120796266A (zh) * | 2024-07-08 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 一种降低hbv基因表达的反义寡核苷酸及其应用 |
| CN119799705B (zh) * | 2024-07-08 | 2025-12-12 | 杭州天龙药业有限公司 | 靶向调控HBV基因表达的siRNA及其应用 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| US5780219A (en) | 1989-07-11 | 1998-07-14 | Gen-Probe Incorporated | Nucleic acid amplification oligonucleotides and probes to human hepatitis B virus |
| GB9006924D0 (en) | 1990-03-28 | 1990-05-23 | Imperial College | Prognosis of hepatitis infection |
| US5610050A (en) | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
| ATE142690T1 (de) | 1990-04-20 | 1996-09-15 | Gen Hospital Corp | Methoden zur verhinderung von viralen replikationen |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| AU8412991A (en) * | 1990-07-27 | 1992-03-02 | Chiron Corporation | Large comb-type branched polynucleotides |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0618924B1 (en) | 1991-12-23 | 2001-02-14 | Bayer Corporation | Hbv amplifier probes for use in solution phase sandwich hybridization assays |
| US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| US6017756A (en) | 1992-05-14 | 2000-01-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting hepatitis B virus replication |
| US20030068301A1 (en) * | 1992-05-14 | 2003-04-10 | Kenneth Draper | Method and reagent for inhibiting hepatitis B virus replication |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| US5736334A (en) | 1993-04-12 | 1998-04-07 | Abbott Laboratories | Nucleotide sequences and process for amplifying and detection of hepatitis B viral DNA |
| EP0785996A1 (en) | 1993-07-13 | 1997-07-30 | Abbott Laboratories | Nucleotide sequences and process for amplifying and detection of hepatitis b virus |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| WO1995017414A1 (en) * | 1993-12-23 | 1995-06-29 | Apollon, Inc. | Anti-hepatitis b viral oligonucleotides |
| US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
| GB9401987D0 (en) | 1994-02-02 | 1994-03-30 | Imperial College | Modified nucleic acid |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5856459A (en) | 1995-06-06 | 1999-01-05 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
| US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US6217858B1 (en) | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| ZA973367B (en) | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| CN1057302C (zh) * | 1997-08-27 | 2000-10-11 | 中国科学院上海生物化学研究所 | 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸 |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| CN1081069C (zh) * | 1998-08-14 | 2002-03-20 | 饶纬华 | 乙型肝炎治疗性疫苗及其制备方法 |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US20040002153A1 (en) * | 1999-07-21 | 2004-01-01 | Monia Brett P. | Modulation of PTEN expression via oligomeric compounds |
| EP1212416A2 (en) | 1999-08-31 | 2002-06-12 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based modulators of gene expression |
| WO2001038498A2 (en) | 1999-11-24 | 2001-05-31 | Pharmasset, Ltd. | A new genotype of hepatitis b virus |
| AU2358201A (en) | 1999-12-03 | 2001-06-12 | Innogenetics N.V. | New hbv sequences |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| EP1152063A1 (en) | 2000-05-03 | 2001-11-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Method of diagnosing HBV infection stages |
| WO2002000613A2 (en) | 2000-06-27 | 2002-01-03 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| EP1383782A1 (en) | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| US20080161256A1 (en) | 2001-05-18 | 2008-07-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| US20030143527A1 (en) | 2001-10-09 | 2003-07-31 | Venkatakrishna Shyamala | Identification of oligonucleotides for the capture, detection and quantitation of hepatitis B viral DNA |
| JP2005507660A (ja) | 2001-10-16 | 2005-03-24 | アビ バイオファーマ， インコーポレイテッド | ｓｓＲＮＡウイルス感染の処置のためのアンチセンス抗ウイルス剤および方法 |
| US20050266422A1 (en) | 2002-02-20 | 2005-12-01 | Sirna Therapeutics, Inc. | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides |
| WO2003087351A1 (en) | 2002-04-12 | 2003-10-23 | Melbourne Health | Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof |
| US7015317B2 (en) | 2002-05-02 | 2006-03-21 | Abbott Laboratories | Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids |
| ATE519861T1 (de) | 2002-06-14 | 2011-08-15 | Gen Probe Inc | Zusammensetzungen zum nachweis von hepatitis-b- virus |
| US7923547B2 (en) | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1572095B1 (en) | 2002-09-13 | 2015-06-10 | Novartis AG | Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| AU2003295600A1 (en) | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| ATE554185T1 (de) | 2003-02-27 | 2012-05-15 | Alnylam Pharmaceuticals Inc | Verfahren und konstrukte zur bewertung von rnai- zielen und effektormolekülen |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US20040191776A1 (en) | 2003-03-21 | 2004-09-30 | Pei-Jer Chen | Method for genotyping and quantifying Hepatitis B Virus |
| US20040185452A1 (en) | 2003-03-21 | 2004-09-23 | Pei-Jer Chen | Identification of single nucleotide polymorphisms |
| US7067249B2 (en) | 2003-05-19 | 2006-06-27 | The University Of Hong Kong | Inhibition of hepatitis B virus (HBV) replication by RNA interference |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| EP2270162B1 (en) | 2003-06-12 | 2018-10-03 | Alnylam Pharmaceuticals Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP1493822A1 (de) | 2003-07-02 | 2005-01-05 | Labor Becker, Olgemoeller & Kollegen GbR | Detektionsverfahren für Nucleinsäuren mit interner Amplifikationskontrolle |
| KR100647277B1 (ko) | 2003-08-14 | 2006-11-17 | 삼성전자주식회사 | Ｂ형 간염 검사용 ｐｃｒ 프라이머 세트 및 이를 포함하는 ｂ형 간염 검사 키트 |
| WO2005021800A2 (en) | 2003-08-22 | 2005-03-10 | Sirna Therapeutics, Inc. | Detection and quantitation of nucleic acid molecules in biological samples |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| DE10339927A1 (de) | 2003-08-29 | 2005-03-24 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen |
| WO2005021751A1 (en) | 2003-09-01 | 2005-03-10 | Patrick Arbuthnot | A self-processing rna expression cassette |
| CA2538252C (en) | 2003-09-18 | 2014-02-25 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| JP2007520461A (ja) | 2003-12-16 | 2007-07-26 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 肝炎ウイルスの負荷を変えるための方法および化合物 |
| ES2332712T3 (es) | 2003-12-16 | 2010-02-11 | Bio-Rad Pasteur | Oligonucleotidos para la deteccion del virus de la hepatitis b. |
| WO2005116204A1 (ja) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| EP1789553B1 (en) | 2004-06-30 | 2014-03-26 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
| EP1799814B1 (en) | 2004-09-28 | 2011-03-30 | Melbourne Health | Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
| WO2006039739A1 (en) | 2004-10-13 | 2006-04-20 | Melbourne Health | Hepatitis b viral (hbv) mutants detection and application |
| EP2316942B1 (en) | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| EP1696040A1 (en) | 2005-02-28 | 2006-08-30 | Eurofins Viralliance, Inc. | Method of genotyping and phenotyping hepatitis B viruses resistant to antiviral molecules |
| US20060205040A1 (en) | 2005-03-03 | 2006-09-14 | Rangarajan Sampath | Compositions for use in identification of adventitious viruses |
| WO2006096018A1 (en) | 2005-03-09 | 2006-09-14 | Mogam Biotechnology Research Institute | Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same |
| US20060258610A1 (en) * | 2005-05-12 | 2006-11-16 | Isis Pharmaceuticals, Inc. | Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness |
| GB0519169D0 (en) | 2005-09-21 | 2005-10-26 | Leuven K U Res & Dev | Novel anti-viral strategy |
| GB0522578D0 (en) | 2005-11-04 | 2005-12-14 | King S College London | Ribozymal nucleic acid |
| WO2007078029A1 (en) | 2006-01-05 | 2007-07-12 | Catch By Gene Co., Ltd. | A quantitative method for hbv-dna, a primer and probe for detecting hbv-dna, and a detecting kit comprising the same |
| WO2007084567A2 (en) | 2006-01-17 | 2007-07-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus |
| EP1991677A2 (en) | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| US8178503B2 (en) | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| US8198253B2 (en) * | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
| DE602006008150D1 (de) | 2006-10-12 | 2009-09-10 | Bio Rad Pasteur | Doppelsträngige Sonden zur Fluoreszenzdetektion von Nukleinsäuren |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CN101589143A (zh) * | 2006-11-27 | 2009-11-25 | Isis药物公司 | 用于治疗高胆固醇血症的方法 |
| AU2007337897A1 (en) | 2006-12-22 | 2008-07-03 | Imuthes Limited | Lipids and their use as non-viral delivery vehicle |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| US8232257B2 (en) | 2007-03-27 | 2012-07-31 | University Of Iowa Research Foundation | RNA interference mediated inactivation of hepatitis B virus in a subject |
| EP2164965B1 (en) | 2007-05-29 | 2013-09-11 | University Of The Witwatersrand, Johannesburg | A primary micro rna expression cassette |
| CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| US9434997B2 (en) | 2007-08-24 | 2016-09-06 | Lawrence Livermore National Security, Llc | Methods, compounds and systems for detecting a microorganism in a sample |
| KR20100069679A (ko) | 2007-09-17 | 2010-06-24 | 재단법인 목암생명공학연구소 | ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법 |
| EP2205617A4 (en) | 2007-11-06 | 2013-10-16 | Siemens Healthcare Diagnostics | HEPATITIS B-VIRUS-SPECIFIC OLIGONUCLEOTIDE SEQUENCES |
| KR20100105648A (ko) * | 2007-12-03 | 2010-09-29 | 엔즌 파마슈티칼스, 인코포레이티드 | Ｐｉｋ３ｃａ 발현 조절용 ｒｎａ 길항제 화합물 |
| US20100317599A1 (en) * | 2008-02-13 | 2010-12-16 | Alrik Pieter Los | Process for the production of a peptide |
| CN101565756B (zh) | 2008-04-25 | 2013-07-10 | 中山大学达安基因股份有限公司 | 一种乙型肝炎病毒核苷类似物耐药相关突变检测试剂盒 |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| US20100015708A1 (en) | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
| TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| US8293474B2 (en) | 2008-07-02 | 2012-10-23 | National Health Research Institutes | Oligonucleotides and use thereof for determining deletion in HBV Pre-S region |
| CN102083983B (zh) | 2008-08-01 | 2014-04-16 | 苏州瑞博生物技术有限公司 | 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用 |
| KR101773551B1 (ko) | 2008-10-15 | 2017-08-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | 인자 １１ 발현의 조정 |
| US20100211327A1 (en) | 2009-02-03 | 2010-08-19 | Prosetta Bioconformatics, Inc. | Methods and Systems for Viral Diagnosis |
| US8815514B2 (en) | 2009-07-02 | 2014-08-26 | Co-Diagnostics, Inc. | Detection primers for nucleic acid extension or amplification reactions |
| BR112012008865A2 (pt) | 2009-10-16 | 2019-09-24 | Glaxo Group Ltd | inibidores de hbv anti-sentido. |
| US9410189B2 (en) | 2010-04-30 | 2016-08-09 | Co-Diagnostics, Inc. | Methods of preventing non-specific reactions of nucleotide sequences |
| US20130137090A1 (en) | 2010-07-06 | 2013-05-30 | Aptateck Bio Ltd. | Nucleic acid aptamer-based diagnostic methods with novel techniques for signal enhancement |
| US9029341B2 (en) * | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| WO2012045894A1 (es) | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b |
| LT3124610T (lt) | 2010-10-28 | 2019-08-12 | Benitec Biopharma Limited | Hbv gydymas |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| WO2012145674A1 (en) | 2011-04-21 | 2012-10-26 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| EA024762B9 (ru) | 2011-06-30 | 2017-04-28 | Эрроухэд Рисерч Корпорейшн | Композиции и способы ингибирования экспрессии генов вируса гепатита в |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| US11511972B1 (en) | 2019-09-26 | 2022-11-29 | Versatile, Inc. | System for tracking lifting events at a construction site |
-
2012
- 2012-04-20 RS RS20210190A patent/RS61447B1/sr unknown
- 2012-04-20 CN CN201280025777.2A patent/CN103582648B/zh active Active
- 2012-04-20 UA UAA201313518A patent/UA118951C2/uk unknown
- 2012-04-20 EP EP19155538.2A patent/EP3505528B1/en active Active
- 2012-04-20 SG SG2013078043A patent/SG194555A1/en unknown
- 2012-04-20 HU HUE19155538A patent/HUE053401T2/hu unknown
- 2012-04-20 PE PE2018000483A patent/PE20181267A1/es unknown
- 2012-04-20 AU AU2012245243A patent/AU2012245243B2/en active Active
- 2012-04-20 EP EP20209058.5A patent/EP3816288A3/en active Pending
- 2012-04-20 TW TW101114260A patent/TWI548745B/zh active
- 2012-04-20 EP EP12773736.9A patent/EP2699583A4/en not_active Withdrawn
- 2012-04-20 US US13/452,703 patent/US8642752B2/en active Active
- 2012-04-20 PT PT191555382T patent/PT3505528T/pt unknown
- 2012-04-20 DK DK19155538.2T patent/DK3505528T3/da active
- 2012-04-20 PH PH1/2019/502377A patent/PH12019502377A1/en unknown
- 2012-04-20 KR KR1020207026891A patent/KR20200110822A/ko not_active Ceased
- 2012-04-20 CN CN202010047402.2A patent/CN111172162A/zh active Pending
- 2012-04-20 SI SI201231882T patent/SI3505528T1/sl unknown
- 2012-04-20 JP JP2014506595A patent/JP6042871B2/ja active Active
- 2012-04-20 LT LTEP19155538.2T patent/LT3505528T/lt unknown
- 2012-04-20 CR CR20190207A patent/CR20190207A/es unknown
- 2012-04-20 PL PL19155538T patent/PL3505528T3/pl unknown
- 2012-04-20 NZ NZ616512A patent/NZ616512A/en unknown
- 2012-04-20 KR KR1020197036206A patent/KR102247463B1/ko active Active
- 2012-04-20 KR KR1020137030465A patent/KR102055331B1/ko active Active
- 2012-04-20 SM SM20210084T patent/SMT202100084T1/it unknown
- 2012-04-20 MX MX2013012196A patent/MX340408B/es active IP Right Grant
- 2012-04-20 EP EP17186598.3A patent/EP3312189A1/en not_active Withdrawn
- 2012-04-20 MX MX2016004337A patent/MX347253B/es unknown
- 2012-04-20 ES ES19155538T patent/ES2856266T3/es active Active
- 2012-04-20 MY MYPI2013701973A patent/MY169474A/en unknown
- 2012-04-20 EA EA201391572A patent/EA029137B1/ru unknown
- 2012-04-20 RU RU2013151843A patent/RU2667524C2/ru not_active Application Discontinuation
- 2012-04-20 NZ NZ705820A patent/NZ705820A/en unknown
- 2012-04-20 CA CA2833766A patent/CA2833766C/en active Active
- 2012-04-20 WO PCT/US2012/034550 patent/WO2012145697A1/en not_active Ceased
- 2012-04-20 PE PE2013002380A patent/PE20141177A1/es active IP Right Grant
- 2012-04-20 CN CN201610555441.7A patent/CN106191060B/zh active Active
- 2012-04-20 SG SG10201604074TA patent/SG10201604074TA/en unknown
-
2013
- 2013-10-14 IL IL228874A patent/IL228874B/en active IP Right Grant
- 2013-10-14 ZA ZA2013/07620A patent/ZA201307620B/en unknown
- 2013-10-17 PH PH12013502157A patent/PH12013502157A1/en unknown
- 2013-10-21 CL CL2013003053A patent/CL2013003053A1/es unknown
- 2013-10-21 DO DO2013000246A patent/DOP2013000246A/es unknown
- 2013-10-28 CR CR20130551A patent/CR20130551A/es unknown
- 2013-11-19 CO CO13271891A patent/CO6862103A2/es active IP Right Grant
- 2013-12-20 US US14/137,111 patent/US9034841B2/en active Active
-
2014
- 2014-08-20 US US14/464,449 patent/US9127278B2/en active Active
-
2015
- 2015-07-07 US US14/793,622 patent/US9677076B2/en active Active
-
2016
- 2016-11-10 JP JP2016219348A patent/JP6426678B2/ja active Active
-
2017
- 2017-05-05 US US15/587,668 patent/US20170369883A1/en not_active Abandoned
-
2018
- 2018-10-23 JP JP2018199169A patent/JP6743106B2/ja active Active
-
2019
- 2019-07-25 US US16/522,490 patent/US20200190520A1/en not_active Abandoned
- 2019-07-25 IL IL268257A patent/IL268257A/en unknown
-
2021
- 2021-02-11 HR HRP20210244TT patent/HRP20210244T1/hr unknown
- 2021-02-16 CY CY20211100131T patent/CY1124327T1/el unknown
- 2021-07-30 US US17/389,599 patent/US20220064650A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20130551A (es) | Modulación de la expresión del virus de la hepatitis b (vhb) | |
| CY1124469T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
| MX2016002587A (es) | Modulacion de la expresion de precalicreina (pkk). | |
| MX2016014140A (es) | Composiciones y metodos para modular la expresion de pkk. | |
| NZ755605A (en) | Compositions for modulating tau expression | |
| UA116087C2 (uk) | Композиція для лікування вірусу гепатиту c | |
| MX2022005200A (es) | Composiciones y metodos para modular la expresion de angiotensinogeno. | |
| CY1122442T1 (el) | Μεθοδοι για την αγωγη ηπατιτιδας c | |
| UY34474A (es) | Composiciones, forma de dosificación y métodos para tratar el virus de la hepatitis C. | |
| EA201791633A1 (ru) | Способ точной модификации растения посредством транзиентной экспрессии гена | |
| EA201491953A1 (ru) | СОЕДИНЕНИЯ НА ОСНОВЕ МИКРОРНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-21 | |
| EA201790630A1 (ru) | Способы получения рибозидов | |
| EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201390230A1 (ru) | Замещенные аналоги нуклеотидов | |
| UY35873A (es) | ?composiciones y métodos para el control de virus en el ácaro varroa y las abejas?. | |
| EA201391152A1 (ru) | Ингибиторы вируса гепатита с | |
| MX371093B (es) | Compuestos de microarn y metodos para modular al mir-122. | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| MX347692B (es) | Inhibidores del virus de la hepatitis c. | |
| EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
| AU2013318309A8 (en) | Methods for treating hepatitis C | |
| EA201791807A1 (ru) | Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич | |
| EA201790778A1 (ru) | Фармацевтические композиции длительного действия от гепатита с | |
| EA201791014A1 (ru) | Композиции на основе irna против вируса гепатита в (hbv) и способы их применения | |
| HK1195316A (en) | Modulation of hepatitis b virus (hbv) expression |